Abeona Therapeutics (NASDAQ:ABEO) SVP Brendan O’malley Sells 13,578 Shares

Abeona Therapeutics Inc. (NASDAQ:ABEO) SVP Brendan O’malley sold 13,578 shares of the business’s stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $5.33, for a total value of $72,370.74. Following the completion of the sale, the senior vice president owned 451,134 shares of the company’s stock, valued at approximately $2,404,544.22. This trade represents a 2.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Abeona Therapeutics Price Performance

ABEO stock opened at $5.36 on Friday. The company’s 50-day moving average price is $5.07 and its two-hundred day moving average price is $5.64. The firm has a market cap of $290.46 million, a P/E ratio of 4.36 and a beta of 1.12. The company has a quick ratio of 9.53, a current ratio of 9.74 and a debt-to-equity ratio of 0.06. Abeona Therapeutics Inc. has a 12 month low of $3.93 and a 12 month high of $7.54.

Abeona Therapeutics (NASDAQ:ABEO) last issued its earnings results on Wednesday, November 12th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.17. On average, analysts anticipate that Abeona Therapeutics Inc. will post -1.16 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on ABEO shares. HC Wainwright restated a “buy” rating and issued a $20.00 target price on shares of Abeona Therapeutics in a report on Monday, October 13th. Wall Street Zen cut shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Abeona Therapeutics in a research report on Wednesday. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $20.00.

Institutional Trading of Abeona Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Boone Capital Management LLC purchased a new stake in Abeona Therapeutics in the 2nd quarter worth approximately $7,126,000. AWM Investment Company Inc. purchased a new position in shares of Abeona Therapeutics during the 2nd quarter valued at $2,670,000. Y Intercept Hong Kong Ltd bought a new position in shares of Abeona Therapeutics in the second quarter worth $581,000. Simplify Asset Management Inc. raised its position in shares of Abeona Therapeutics by 36.7% in the second quarter. Simplify Asset Management Inc. now owns 558,584 shares of the biopharmaceutical company’s stock worth $3,173,000 after buying an additional 150,000 shares in the last quarter. Finally, Los Angeles Capital Management LLC purchased a new position in Abeona Therapeutics during the second quarter worth about $1,523,000. Hedge funds and other institutional investors own 80.56% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.